ArticleAmerican journal of hematology2022

TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.

Hua-Jay J Cherng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.